Drug Profile
Research programme: cancer and inflammatory disease antibody-drug conjugates - Enzo Biochem/Innate Pharma
Latest Information Update: 05 Apr 2023
Price :
$50
*
At a glance
- Originator Innate Pharma
- Developer Enzo Life Sciences; Innate Pharma
- Class Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Inflammation
Most Recent Events
- 03 Apr 2023 Innate Pharma and Takeda agree to co-develop, manufacture and co-commercialize Antibody dependent drug conjugates for Celiac disease
- 28 Jul 2018 No recent reports of development identified for research development in Cancer in France
- 28 Jul 2018 No recent reports of development identified for research development in Cancer in USA